December 10, 2024

SAN DIEGO — As re­searchers ex­plore more po­ten­tial ben­e­fits of GLP-1 med­i­cines, a new ret­ro­spec­tive study is sug­gest­ing the drug class’ po­ten­tial to treat ve­nous

Ma­chine learn­ing and AI have sparked a trans­for­ma­tion in drug dis­cov­ery, but crack­ing the bi­ol­o­gy is still para­mount. That’s the think­ing be­hind a new col­lab­o­ra­tion

In his first ma­jor in­ter­view since se­cur­ing an­oth­er term in the White House, Pres­i­dent-elect Don­ald Trump re­it­er­at­ed con­cerns with the dis­proven link be­tween child­hood vac­cines

Au­thor­i­ties have ar­rest­ed a per­son of in­ter­est in con­nec­tion with the fa­tal shoot­ing of Unit­ed­Health­care CEO Bri­an Thomp­son. The ar­rest came af­ter a days-long man­hunt

San Diego start­up Bel­har­ra Ther­a­peu­tics, a biotech cre­at­ing small mol­e­cule can­cer and im­munol­o­gy med­i­cines, has laid off 21 em­ploy­ees, End­points News has con­firmed. Bel­har­ra, from

SAN DIEGO — Two years af­ter pulling Blenrep from the mar­ket, GSK is po­si­tion­ing for a re­launch. This time, the com­pa­ny says it’s com­ing from

The cost-ef­fec­tive­ness watch­dog ICER found that Ver­tex’s fu­ture non-opi­oid treat­ment for acute pain could be cost-sav­ing, but on­ly at a low price, ac­cord­ing to a